Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Ecdysterone and Tamoxifen Interaction: Avoid | Peptide Database

Compound Profiles Ecdysterone Phytoecdysteroid | Natural Anabolic & Performance Enhancer Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Ecdysterone

Phytoecdysteroid | Natural Anabolic & Performance Enhancer

Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling.

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Ecdysterone with Tamoxifen?

Combining Ecdysterone with Tamoxifen is not recommended. Both Ecdysterone and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ecdysterone and Tamoxifen safe together?

This combination carries significant risk. Both Ecdysterone and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ecdysterone and Tamoxifen?

Both Ecdysterone and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ecdysterone and Tamoxifen?

Ecdysterone has a half-life of ~4-9 hours and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

RAD-140 has shown potent anabolic effects on skeletal muscle in preclinical models, with increases in lean body mass comparable to moderate doses of testosterone. Users report meaningful increases in lean mass over 8-12 week cycles at 10-20 mg/day, though controlled human trial data for this indication is lacking. Dose-dependent increases in strength have been reported anecdotally and are consistent with the compound's mechanism of action as a potent AR agonist in skeletal muscle. Strength gains are typically noticed within 2-4 weeks of starting a cycle. The combination of anabolic activity without estrogenic water retention makes RAD-140 a compound of interest for simultaneous fat loss and lean mass gain. Preclinical data supports a favorable shift in body composition, though human data is limited. RAD-140 has entered Phase 1 clinical trials for the treatment of ER+/AR+/HER2- metastatic breast cancer. The rationale is that AR activation can suppress estrogen-driven tumor growth in AR-positive breast cancers. Early results demonstrated tolerability and preliminary signals of anti-tumor activity. Originally developed for conditions involving muscle wasting (cachexia, sarcopenia, age-related muscle loss). Preclinical data supports the potential to preserve or restore muscle mass in catabolic states, but no human efficacy trials have been completed for this indication. In vitro studies have shown that RAD-140 protects hippocampal neurons from kainate-induced excitotoxicity and beta-amyloid-induced cell death, suggesting potential relevance to neurodegenerative diseases. This remains a preclinical observation only.

Source: peptide-db.com ↗

Community Research

Join others researching Cortagen — share findings, ask questions, and learn from real experiences Cortagen is a Khavinson bioregulator tetrapeptide (AEDP) with primary effects on the brain and central nervous system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it regulates inflammatory responses in the nervous system, restores balance between pro- and anti-oxidative processes, and stimulates interleukin-2 expression. Research shows potential benefits for ischemic brain injury recovery, nerve regeneration, and reducing autoimmune reactions affecting the CNS. Cortagen works through epigenetic regulation by penetrating cell nuclei and interacting with DNA to modulate gene expression. In the heart, it affects genes including Pass1, Hsc70, Bmp2, Wnt4, Eps15, and Eps15-rs. It powerfully regulates inflammatory responses in the nervous system, helping restore proper balance between oxidative and anti-oxidative processes. Cortagen stimulates IL-2 expression and helps regulate immune function, particularly by reducing autoimmune reactions.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Naltrexone is administered orally. Full-dose naltrexone (50 mg) is available as a standard pharmaceutical tablet (ReVia). Low-Dose Naltrexone (1-4.5 mg) is typically obtained as a compounded capsule or liquid from a compounding pharmacy, as commercial formulations at these low doses are not widely manufactured. Some practitioners prescribe commercially available 50 mg tablets to be dissolved in measured volumes of water or other vehicle for precise low-dose self-preparation, though compounded capsules are preferred for dosing accuracy. Low-Dose Naltrexone (LDN) - Standard Protocol 1.5 mg, titrate to 4.5 mg Once daily at bedtime Oral LDN - Ultra-Low Starting Dose (Sensitive Patients) 0.5-1.0 mg, titrate slowly to 4.5 mg Full-Dose - Opioid Dependence (FDA-Approved) 50 mg/day Once daily Full-Dose - Alcohol Dependence (FDA-Approved)

Source: peptide-db.com ↗
Potential benefits

What respiratory benefits have been proven in human trials for Bronchogen?

Clinical evidence on Bronchogen specifically is limited. Most research comes from Russian sources showing improvements in respiratory function when combined with other Khavinson peptides. Clear human efficacy data from double-blind trials doesn't exist in English-language literature.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →